ES2659434T3 - Procedimientos de producción de 4-cicloalquiloxibencensulfonamidas - Google Patents

Procedimientos de producción de 4-cicloalquiloxibencensulfonamidas Download PDF

Info

Publication number
ES2659434T3
ES2659434T3 ES16193142.3T ES16193142T ES2659434T3 ES 2659434 T3 ES2659434 T3 ES 2659434T3 ES 16193142 T ES16193142 T ES 16193142T ES 2659434 T3 ES2659434 T3 ES 2659434T3
Authority
ES
Spain
Prior art keywords
group
mmol
reaction
formula
benzenesulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16193142.3T
Other languages
English (en)
Spanish (es)
Inventor
Tsuyoshi Shinozuka
Hiroyuki Kobayashi
Sayaka SUZUKI
Kyosuke TANAKA
Hiroko KIMOTO
Yuki Domon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ES2659434T3 publication Critical patent/ES2659434T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16193142.3T 2012-02-09 2013-02-08 Procedimientos de producción de 4-cicloalquiloxibencensulfonamidas Active ES2659434T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012025754 2012-02-09
JP2012259122 2012-11-27
JP2012259122 2012-11-27

Publications (1)

Publication Number Publication Date
ES2659434T3 true ES2659434T3 (es) 2018-03-15

Family

ID=48947609

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16193142.3T Active ES2659434T3 (es) 2012-02-09 2013-02-08 Procedimientos de producción de 4-cicloalquiloxibencensulfonamidas
ES13746373.3T Active ES2613078T3 (es) 2012-02-09 2013-02-08 Derivado de cicloalcano

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13746373.3T Active ES2613078T3 (es) 2012-02-09 2013-02-08 Derivado de cicloalcano

Country Status (30)

Country Link
US (3) US8889741B2 (enExample)
EP (2) EP2813491B1 (enExample)
JP (2) JP5997710B2 (enExample)
KR (1) KR20140127238A (enExample)
CN (1) CN104185629B (enExample)
AU (1) AU2013218592B2 (enExample)
BR (1) BR112014019478A2 (enExample)
CA (1) CA2864222C (enExample)
CO (1) CO7151511A2 (enExample)
CY (1) CY1118572T1 (enExample)
DK (1) DK2813491T3 (enExample)
ES (2) ES2659434T3 (enExample)
HR (1) HRP20161713T1 (enExample)
HU (2) HUE037048T2 (enExample)
IL (1) IL234014A (enExample)
IN (1) IN2014MN01577A (enExample)
LT (1) LT2813491T (enExample)
MX (1) MX349354B (enExample)
NZ (1) NZ628096A (enExample)
PH (2) PH12014501804B1 (enExample)
PL (1) PL2813491T3 (enExample)
PT (1) PT2813491T (enExample)
RS (1) RS55671B1 (enExample)
RU (1) RU2635354C2 (enExample)
SG (1) SG11201404707VA (enExample)
SI (1) SI2813491T1 (enExample)
SM (2) SMT201700053T1 (enExample)
TW (1) TWI612042B (enExample)
WO (1) WO2013118854A1 (enExample)
ZA (1) ZA201405801B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
BR112014029161A2 (pt) 2012-05-22 2017-06-27 Genentech Inc benzamidas n-substituídas e seu uso no tratamento de dor
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
BR112015022488A2 (pt) 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
EP2974730B1 (en) * 2013-03-14 2018-01-31 Daiichi Sankyo Company, Limited Drug for respiratory diseases
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
CR20160296A (es) 2013-11-27 2016-09-20 Genentech Inc Benzamidas sustituidas y métodos para usarlas
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016191312A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
PE20181003A1 (es) 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
JPWO2017078123A1 (ja) * 2015-11-06 2018-09-13 第一三共株式会社 ジメトキシベンジル基の脱離方法
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
KR102366077B1 (ko) * 2016-05-20 2022-02-21 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
SG11201903348UA (en) * 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
MA46615A (fr) * 2016-10-27 2019-09-04 Bristol Myers Squibb Co Inhibiteurs de nav1.7 de type acyl-sulfonamide
KR20190086772A (ko) * 2016-12-09 2019-07-23 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
WO2018175707A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
AU2018338098B2 (en) 2017-09-20 2024-02-22 Abm Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
EP3759098A1 (en) * 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
CA3104913A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
KR20210107698A (ko) * 2018-12-26 2021-09-01 라퀄리아 파마 인코포레이티드 Nav1.7 및 Nav1.8 차단제로 쓰이는 헤테로환 유도체
US12625275B2 (en) * 2023-01-18 2026-05-12 Qualcomm Incorporated Virtual positioning signal measurements

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
KR20080021030A (ko) * 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
HUE025013T2 (hu) * 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
JP5872552B2 (ja) * 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
CA2804593C (en) * 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
ES2586213T3 (es) * 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Also Published As

Publication number Publication date
LT2813491T (lt) 2017-02-10
CA2864222C (en) 2016-10-25
HRP20161713T1 (hr) 2017-02-10
HUE037048T2 (hu) 2018-08-28
BR112014019478A2 (pt) 2019-05-28
AU2013218592A1 (en) 2014-09-18
DK2813491T3 (en) 2017-02-13
EP2813491A4 (en) 2015-08-12
TW201339152A (zh) 2013-10-01
US8889741B2 (en) 2014-11-18
PH12014501804A1 (en) 2014-11-17
US20150018551A1 (en) 2015-01-15
ZA201405801B (en) 2015-12-23
KR20140127238A (ko) 2014-11-03
CO7151511A2 (es) 2014-12-29
CN104185629A (zh) 2014-12-03
US20170001984A1 (en) 2017-01-05
NZ628096A (en) 2016-06-24
PL2813491T3 (pl) 2017-08-31
RU2014136463A (ru) 2016-03-27
MX349354B (es) 2017-07-24
SMT201700053B (it) 2017-03-08
EP3144300A1 (en) 2017-03-22
JP2017008093A (ja) 2017-01-12
AU2013218592B2 (en) 2016-12-22
JP5997710B2 (ja) 2016-09-28
CA2864222A1 (en) 2013-08-15
CY1118572T1 (el) 2017-07-12
PT2813491T (pt) 2017-02-10
EP3144300B1 (en) 2017-12-20
IL234014A0 (en) 2014-09-30
IL234014A (en) 2017-09-28
WO2013118854A1 (ja) 2013-08-15
SI2813491T1 (sl) 2017-02-28
RU2635354C2 (ru) 2017-11-13
ES2613078T3 (es) 2017-05-22
IN2014MN01577A (enExample) 2015-05-08
JP6154052B2 (ja) 2017-06-28
MX2014009637A (es) 2015-06-23
US20140045862A1 (en) 2014-02-13
HUE031450T2 (en) 2017-07-28
JPWO2013118854A1 (ja) 2015-05-11
RS55671B1 (sr) 2017-06-30
SG11201404707VA (en) 2014-10-30
SMT201700053T1 (it) 2017-03-08
EP2813491B1 (en) 2016-11-02
PH12014501804B1 (en) 2014-11-17
US9845313B2 (en) 2017-12-19
EP2813491A1 (en) 2014-12-17
TWI612042B (zh) 2018-01-21
US9493448B2 (en) 2016-11-15
HK1203503A1 (en) 2015-10-30
PH12015502675A1 (en) 2017-04-24
CN104185629B (zh) 2017-10-13

Similar Documents

Publication Publication Date Title
ES2613078T3 (es) Derivado de cicloalcano
KR102757890B1 (ko) 화합물, 조성물 및 방법
ES2663798T3 (es) Fármaco para enfermedades respiratorias
ES2586213T3 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
ES2556752T3 (es) Ligandos de receptores cannabinoides
ES2624421T3 (es) Derivados de carbamato/urea que contienen anillos de piperidina y piperazina como inhibidores del receptor H3.
EP4320103A1 (en) Pyrimidine based ras modulators and uses thereof
HK1203503B (en) Cycloalkane derivative
WO2024092185A1 (en) Acyl sulfonamide compounds as inhibitors of polyomavirus
HK1219668B (en) Drug for respiratory diseases
HK1219668A1 (en) Drug for respiratory diseases